Sernova Biotherapeutics Announces Warrant Amendments

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - February 20, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSH0) ("the Company"), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced that, subject to approval from the TSX, the Company intends to amend some of its outstanding warrants.The Company issued 20,852,100 warrants pursuant to a private placement unit offering on Sep ...